CW Advisors LLC Grows Position in Pfizer Inc. $PFE

CW Advisors LLC raised its position in Pfizer Inc. (NYSE:PFE) by 34.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 708,407 shares of the biopharmaceutical company’s stock after buying an additional 180,608 shares during the quarter. CW Advisors LLC’s holdings in Pfizer were worth $17,172,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the business. Acorns Advisers LLC boosted its stake in Pfizer by 32.8% during the 2nd quarter. Acorns Advisers LLC now owns 12,503 shares of the biopharmaceutical company’s stock worth $303,000 after purchasing an additional 3,087 shares during the period. JT Stratford LLC raised its holdings in shares of Pfizer by 72.4% in the second quarter. JT Stratford LLC now owns 17,521 shares of the biopharmaceutical company’s stock valued at $425,000 after buying an additional 7,359 shares during the last quarter. Argyle Capital Partners LLC boosted its stake in shares of Pfizer by 13.7% during the second quarter. Argyle Capital Partners LLC now owns 13,973 shares of the biopharmaceutical company’s stock worth $339,000 after buying an additional 1,686 shares during the period. Twin Peaks Wealth Advisors LLC purchased a new position in shares of Pfizer during the second quarter worth about $134,000. Finally, Nicolet Bankshares Inc. increased its position in Pfizer by 8.4% in the 2nd quarter. Nicolet Bankshares Inc. now owns 34,766 shares of the biopharmaceutical company’s stock valued at $843,000 after acquiring an additional 2,704 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on PFE shares. Sanford C. Bernstein reiterated a “market perform” rating and issued a $30.00 target price on shares of Pfizer in a research note on Friday, October 31st. Citigroup began coverage on shares of Pfizer in a research report on Tuesday. They issued a “neutral” rating and a $26.00 price objective on the stock. Bank of America upped their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Scotiabank started coverage on shares of Pfizer in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 target price for the company. Finally, UBS Group reiterated a “neutral” rating and set a $28.00 price target on shares of Pfizer in a research note on Wednesday, October 1st. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $28.39.

Pfizer Price Performance

Shares of NYSE PFE opened at $25.60 on Thursday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.69. The firm has a market capitalization of $145.53 billion, a P/E ratio of 14.88 and a beta of 0.46. The company’s fifty day moving average is $25.08 and its two-hundred day moving average is $24.65.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.79 by $0.08. The firm had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, December 1st. Stockholders of record on Friday, November 7th were paid a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, November 7th. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. Pfizer’s payout ratio is 100.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.